ENvue Medical Inc (FEED) is a medical device company that is developing and seeking to commercialize medical device product candidates. The company was formerly known as NanoVibronix, Inc. and adopted its current name following a merger completed on February 14, 2025, in which it acquired ENvue Medical Holdings LLC. Revenue generation from commercial products had not been established as of the fiscal year ended December 31, 2024, and management disclosed substantial doubt about the company's ability to continue as a going concern in the 10-K filed April 15, 2026. The company depends on raising additional capital to fund clinical trials and product development, and expects to continue incurring losses. Third-party reimbursement from Medicare, Medicaid, and commercial insurers is identified as a key condition for any future commercially viable market for its products.

Revenue model

The company had not demonstrated a commercial revenue model as of FY2024. Future revenue, if achieved, is expected to depend on product sales through direct or third-party distribution channels, with reimbursement from third-party payers including Medicare, Medicaid, and commercial insurers described as necessary for commercial viability.

Products and services

The company is developing medical device product candidates. Specific product names, indications, or development-stage details are not described in the available filing excerpts.

Customers and end markets

The end market is healthcare, with patients and healthcare providers as the ultimate customers. Third-party payers including Medicare, Medicaid, and commercial insurers are identified as gatekeepers for product reimbursement. The company is subject to HIPAA and GDPR regulations, indicating potential handling of patient health information.

Value-chain role

Pre-commercial medical device developer. The company conducts product development and clinical trials internally and anticipates using third-party distributors for future sales and marketing. As of FY2024, the company had a small planned employee base and described its management systems as inadequate to support future growth.

Geographic exposure

The filing references U.S. federal healthcare regulations as primary compliance obligations, with additional references to EU GDPR and foreign data protection laws, suggesting at least anticipated international operations. Specific revenue by geography is not disclosed in the available excerpts.

Source: SEC 10-K, filed 2026-04-15

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Abbott Laboratories Aethlon Medical Inc BRAIN SCIENTIFIC INC. NANOMIX Corp INVO Fertility Inc Femasys Inc Myomo Inc Valion Bio Inc